Acutus Medical Inc.
| NASDAQ: AFIB | Healthcare / Medical Devices & Instruments / USA |
| 0.7254 | -0.0146 | -1.97% | Vol 18.65K | 1Y Perf -14.93% |
| Oct 3rd, 2023 16:00 DELAYED |
| BID | 0.7200 | ASK | 0.7843 | ||
| Open | 0.7600 | Previous Close | 0.7400 | ||
| Pre-Market | - | After-Market | 0.73 | ||
| - - | 0.00 -0.06% |
| Target Price | 2.00 | Analyst Rating | Hold 3.00 | |
| Potential % | 175.71 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★ 51.09 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★ 52.76 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 20.86 | Earnings Rating | — | |
| Market Cap | 21.22M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.08 | Standard Deviation | 0.27 | |
| Beta | 0.88 |
Today's Price Range 0.72000.7600 | 52W Range 0.40001.96 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 8.58% | ||
| 1 Month | 51.64% | ||
| 3 Months | -16.85% | ||
| 6 Months | -4.52% | ||
| 1 Year | -14.93% | ||
| 3 Years | -97.29% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -89.82 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -55.11 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -58.86 | |||
Return on invested Capital Q | -18.42 | |||
Return on invested Capital Y | -70.34 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 0.66 | ||||
| 3.09 | ||||
| - | ||||
| -1.60 | ||||
| -3.36 | ||||
| 0.68 | ||||
| 2.03 | ||||
| 10.73M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.80 | ||||
| 5.10 | ||||
| 0.40 | ||||
| 0.67 | ||||
| -15.50 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -112.70 | ||||
| -512.50 | ||||
| -466.90 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 11.40M | ||||
| 0.40 | ||||
| 74.90 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.61 | -0.63 | -3.28 |
| Q01 2023 | -0.66 | -0.57 | 13.64 |
| Q04 2022 | -0.70 | 0.41 | 158.57 |
| Q03 2022 | -0.83 | -0.72 | 13.25 |
| Q02 2022 | -0.83 | 0.16 | 119.28 |
| Q01 2022 | -1.10 | -1.11 | -0.91 |
| Q04 2021 | -0.92 | -1.13 | -22.83 |
| Q03 2021 | -0.92 | -0.99 | -7.61 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 9th Nov 2023 |
| Estimated EPS Next Report | -0.57 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 18.65K |
| Shares Outstanding | 29.26K |
| Shares Float | 25.51M |
| Trades Count | 154 |
| Dollar Volume | 13.63K |
| Avg. Volume | 88.54K |
| Avg. Weekly Volume | 62.83K |
| Avg. Monthly Volume | 96.79K |
| Avg. Quarterly Volume | 106.00K |
Acutus Medical Inc. (NASDAQ: AFIB) stock closed at 0.74 per share at the end of the most recent trading day (a 6.23% change compared to the prior day closing price) with a volume of 95.32K shares and market capitalization of 21.22M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 291 people. Acutus Medical Inc. CEO is Vincent J. Burgess.
The one-year performance of Acutus Medical Inc. stock is -14.93%, while year-to-date (YTD) performance is -35.65%. AFIB stock has a five-year performance of %. Its 52-week range is between 0.4 and 1.96, which gives AFIB stock a 52-week price range ratio of 20.86%
Acutus Medical Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.66, a price-to-sale (PS) ratio of 3.09, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -55.11%, a ROC of -58.86% and a ROE of -89.82%. The company’s profit margin is -%, its EBITDA margin is -466.90%, and its revenue ttm is $11.40 Million , which makes it $0.40 revenue per share.
Of the last four earnings reports from Acutus Medical Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Acutus Medical Inc.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for Acutus Medical Inc. is Hold (3), with a target price of $2, which is +175.71% compared to the current price. The earnings rating for Acutus Medical Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Acutus Medical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Acutus Medical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 18.68, ATR14 : 0.07, CCI20 : 100.57, Chaikin Money Flow : -0.03, MACD : 0.04, Money Flow Index : 74.39, ROC : 42.31, RSI : 61.93, STOCH (14,3) : 83.90, STOCH RSI : 0.95, UO : 54.22, Williams %R : -16.10), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Acutus Medical Inc. in the last 12-months were:
Acutus Medical Inc.
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.
CEO: Vincent J. Burgess
Telephone: +1 442 232-6080
Address: 2210 Faraday Avenue, Carlsbad 92008, CA, US
Number of employees: 291
